This schedule includes the controlled substances listed or to be listedby whatever official name, common or usual name, chemical name, or trade namedesignated. In determining that a substance comes within this schedule, theCommission shall find: a potential for abuse less than the substances listed inSchedules I and II; currently accepted medical use in the United States; andabuse may lead to moderate or low physical dependence or high pyschologicaldependence. The following controlled substances are included in this schedule:
(a) Repealed by Session Laws 1973, c. 540, s. 5.
(b) Any material, compound, mixture, or preparation whichcontains any quantity of the following substances having a depressant effect onthe central nervous system unless specifically exempted or listed in anotherschedule:
1. Any substance which contains any quantity of a derivative ofbarbituric acid, or any salt of a derivative of barbituric acid.
2. Chlorhexadol.
3. Repealed by Session Laws 1993, c. 319, s. 5.
4. Lysergic acid.
5. Lysergic acid amide.
6. Methyprylon.
7. Sulfondiethylmethane.
8. Sulfonethylmethane.
9. Sulfonmethane.
9a. Tiletamine and zolazepam or any salt thereof. Some trade orother names for tiletamine‑zolazepam combination product: Telazol. Sometrade or other names for tiletamine:
2‑(ethylamino)‑2‑(2‑thienyl)‑cyclohexanone.Some trade or other names for zolazepam: 4‑(2‑fluorophenyl)‑6,8‑dihydro‑1,3,8‑trimethylpyrazolo‑[3,4‑e][1,4]‑diazepin‑7(1H)‑one. flupyrazapon.
10. Any compound, mixture or preparation containing
(i) Amobarbital.
(ii) Secobarbital.
(iii) Pentobarbital.
or any salt thereof and one or more active ingredientswhich are not included in any other schedule.
11. Any suppository dosage form containing
(i) Amobarbital.
(ii) Secobarbital.
(iii) Pentobarbital.
or any salt of any of these drugs and approved by thefederal Food and Drug Administration for marketing as a suppository.
12. Ketamine.
(c) Nalorphine.
(d) Any material, compound, mixture, or preparation containinglimited quantities of any of the following narcotic drugs, or any salts thereofunless specifically exempted or listed in another schedule:
1. Not more than 1.80 grams of codeine per 100 milliliters ornot more than 90 milligrams per dosage unit with an equal or greater quantityof an isoquinoline alkaloid of opium.
2. Not more than 1.80 grams of codeine per 100 milliliters ornot more than 90 milligrams per dosage unit, with one or more active,nonnarcotic ingredients in recognized therapeutic amounts.
3. Not more than 300 milligrams of dihydrocodeinone per 100milliliters or not more than 15 milligrams per dosage unit with a four‑foldor greater quantity of an isoquinoline alkaloid of opium.
4. Not more than 300 milligrams of dihydrocodeinone per 100milliliters or not more than 15 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
5. Not more than 1.80 grams of dihydrocodeine per 100milliliters or not more than 90 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
6. Not more than 300 milligrams of ethylmorphine per 100milliliters or not more than 15 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
7. Not more than 500 milligrams of opium per 100 milliliters orper 100 grams, or not more than 25 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
8. Not more than 50 milligrams of morphine per 100 millilitersor per 100 grams with one or more active, nonnarcotic ingredients in recognizedtherapeutic amounts.
(e) Any compound, mixture or preparation containing limitedquantities of the following narcotic drugs, which shall include one or moreactive, nonnarcotic, medicinal ingredients in sufficient proportion to conferupon the compound, mixture, or preparation, valuable medicinal qualities otherthan those possessed by the narcotic drug alone:
1. Paregoric, U.S.P.; provided, that no person shall purchaseor receive by any means whatsoever more than one fluid ounce of paregoricwithin a consecutive 24‑hour period, except on prescription issued by aduly licensed physician.
(f) Paregoric, U.S.P., may be dispensed at retail as permittedby federal law or administrative regulation without a prescription only by aregistered pharmacist and no other person, agency or employee may dispenseparegoric, U.S.P., even if under the direct supervision of a pharmacist.
(g) Notwithstanding the provisions of G.S. 90‑91(f), afterthe pharmacist has fulfilled his professional responsibilities and legalresponsibilities required of him in this Article, the actual cash transaction,credit transaction, or delivery of paregoric, U.S.P., may be completed by anonpharmacist. A pharmacist may refuse to dispense a paregoric, U.S.P.,substance until he is satisfied that the product is being obtained formedicinal purposes only.
(h) Paregoric, U.S.P., may only be sold at retail without aprescription to a person at least 18 years of age. A pharmacist must requireevery retail purchaser of a paregoric, U.S.P., substance to furnish suitableidentification, including proof of age when appropriate, in order to purchaseparegoric, U.S.P. The name and address obtained from such identification shallbe entered in the record of disposition to consumers.
(i) The Commission may by regulation except any compound,mixture, or preparation containing any stimulant or depressant substance listedin paragraphs (a)1 and (a)2 of this schedule from the application of all or anypart of this Article if the compound, mixture, or preparation contains one ormore active medicinal ingredients not having a stimulant or depressant effecton the central nervous system; and if the ingredients are included therein insuch combinations, quantity, proportion, or concentration that vitiate thepotential for abuse of the substances which have a stimulant or depressanteffect on the central nervous system.
(j) Any material, compound, mixture, or preparation whichcontains any quantity of the following substances having a stimulant effect onthe central nervous system, including its salts, isomers, and salts of saidisomers whenever the existence of such salts, isomers, and salts of isomers ispossible within the specific chemical designation, unless specifically excludedor listed in some other schedule.
1. Benzphetamine.
2. Chlorphentermine.
3. Clortermine.
4. Repealed by Session Laws 1987, c. 412, s. 10.
5. Phendimetrazine.
(k) Anabolic steroids. The term "anabolic steroid"means any drug or hormonal substance, chemically and pharmacologically relatedto testosterone (other than estrogens, progestins, and corticosteroids) thatpromotes muscle growth, including, but not limited to, the following:
1. Methandrostenolone,
2. Stanozolol,
3. Ethylestrenol,
4. Nandrolone phenpropionate,
5. Nandrolone deconoate,
6. Testosterone propionate,
7. Chorionic gonadotropin,
8. Boldenone,
9. Chlorotestosterone (4‑chlorotestosterone),
10. Clostebol,
11. Dehydrochlormethyltestosterone,
12. Dibydrostestosterone (4‑dihydrotestosterone),
13. Drostanolone,
14. Fluoxymesterone,
15. Formebulone (formebolone),
16. Mesterolene,
17. Methandienone,
18. Methandranone,
19. Methandriol,
20. Methenolene,
21. Methyltestosterone,
22. Mibolerone,
23. Nandrolene,
24. Norethandrolene,
25. Oxandrolone,
26. Oxymesterone,
27. Oxymetholone,
28. Stanolone,
29. Testolactone,
30. Testosterone,
31. Trenbolone, and
32. Any salt, ester, or isomer of a drug or substance describedor listed in this subsection, if that salt, ester, or isomer promotes musclegrowth. Except such term does not include an anabolic steroid which isexpressly intended for administration through implants to cattle or othernonhuman species and which has been approved by the Secretary of Health andHuman Services for such administration. If any person prescribes, dispenses, ordistributes such steroid for human use, such person shall be considered to haveprescribed, dispensed, or distributed an anabolic steroid within the meaning ofthis subsection.
(l) Repealed by Session Laws 2001‑233, s. 3(a).
(m) Any drug product containing gamma hydroxybutyric acid,including its salts, isomers, and salts of isomers, for which an application isapproved under section 505 of the Federal Food, Drug, and Cosmetic Act.
(n) Dronabinol (synthetic) in sesame oil and encapsulated in asoft gelatin capsule in a U.S. Food and Drug Administration approved drugproduct. [Some other names: (6aR‑trans), ‑6a,7,8,10a‑tetrahydro‑6,6,9‑trimethyl‑3‑pentyl‑6H‑dibenzo[b,d]pyran‑1‑o1 or (‑)‑delta‑9‑(trans)‑tetrahydrocannabinol].(1971, c. 919, s. 1; 1973, c. 476, s. 128; c. 540, s.5; c. 1358, ss. 7, 15; 1975, c. 442; 1977, c. 667, s. 3; 1979, c. 434, s. 3;1981, c. 51, s. 9; 1987, c. 412, ss. 8‑10; 1987 (Reg. Sess., 1988), c.1055; 1991, c. 413, s. 1; 1993, c. 319, s. 5; 1999‑370, s. 3; 2000‑140,s. 92.2(b); 2001‑233, ss. 2(b), 3(a), 3(b).)
This schedule includes the controlled substances listed or to be listedby whatever official name, common or usual name, chemical name, or trade namedesignated. In determining that a substance comes within this schedule, theCommission shall find: a potential for abuse less than the substances listed inSchedules I and II; currently accepted medical use in the United States; andabuse may lead to moderate or low physical dependence or high pyschologicaldependence. The following controlled substances are included in this schedule:
(a) Repealed by Session Laws 1973, c. 540, s. 5.
(b) Any material, compound, mixture, or preparation whichcontains any quantity of the following substances having a depressant effect onthe central nervous system unless specifically exempted or listed in anotherschedule:
1. Any substance which contains any quantity of a derivative ofbarbituric acid, or any salt of a derivative of barbituric acid.
2. Chlorhexadol.
3. Repealed by Session Laws 1993, c. 319, s. 5.
4. Lysergic acid.
5. Lysergic acid amide.
6. Methyprylon.
7. Sulfondiethylmethane.
8. Sulfonethylmethane.
9. Sulfonmethane.
9a. Tiletamine and zolazepam or any salt thereof. Some trade orother names for tiletamine‑zolazepam combination product: Telazol. Sometrade or other names for tiletamine:
2‑(ethylamino)‑2‑(2‑thienyl)‑cyclohexanone.Some trade or other names for zolazepam: 4‑(2‑fluorophenyl)‑6,8‑dihydro‑1,3,8‑trimethylpyrazolo‑[3,4‑e][1,4]‑diazepin‑7(1H)‑one. flupyrazapon.
10. Any compound, mixture or preparation containing
(i) Amobarbital.
(ii) Secobarbital.
(iii) Pentobarbital.
or any salt thereof and one or more active ingredientswhich are not included in any other schedule.
11. Any suppository dosage form containing
(i) Amobarbital.
(ii) Secobarbital.
(iii) Pentobarbital.
or any salt of any of these drugs and approved by thefederal Food and Drug Administration for marketing as a suppository.
12. Ketamine.
(c) Nalorphine.
(d) Any material, compound, mixture, or preparation containinglimited quantities of any of the following narcotic drugs, or any salts thereofunless specifically exempted or listed in another schedule:
1. Not more than 1.80 grams of codeine per 100 milliliters ornot more than 90 milligrams per dosage unit with an equal or greater quantityof an isoquinoline alkaloid of opium.
2. Not more than 1.80 grams of codeine per 100 milliliters ornot more than 90 milligrams per dosage unit, with one or more active,nonnarcotic ingredients in recognized therapeutic amounts.
3. Not more than 300 milligrams of dihydrocodeinone per 100milliliters or not more than 15 milligrams per dosage unit with a four‑foldor greater quantity of an isoquinoline alkaloid of opium.
4. Not more than 300 milligrams of dihydrocodeinone per 100milliliters or not more than 15 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
5. Not more than 1.80 grams of dihydrocodeine per 100milliliters or not more than 90 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
6. Not more than 300 milligrams of ethylmorphine per 100milliliters or not more than 15 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
7. Not more than 500 milligrams of opium per 100 milliliters orper 100 grams, or not more than 25 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
8. Not more than 50 milligrams of morphine per 100 millilitersor per 100 grams with one or more active, nonnarcotic ingredients in recognizedtherapeutic amounts.
(e) Any compound, mixture or preparation containing limitedquantities of the following narcotic drugs, which shall include one or moreactive, nonnarcotic, medicinal ingredients in sufficient proportion to conferupon the compound, mixture, or preparation, valuable medicinal qualities otherthan those possessed by the narcotic drug alone:
1. Paregoric, U.S.P.; provided, that no person shall purchaseor receive by any means whatsoever more than one fluid ounce of paregoricwithin a consecutive 24‑hour period, except on prescription issued by aduly licensed physician.
(f) Paregoric, U.S.P., may be dispensed at retail as permittedby federal law or administrative regulation without a prescription only by aregistered pharmacist and no other person, agency or employee may dispenseparegoric, U.S.P., even if under the direct supervision of a pharmacist.
(g) Notwithstanding the provisions of G.S. 90‑91(f), afterthe pharmacist has fulfilled his professional responsibilities and legalresponsibilities required of him in this Article, the actual cash transaction,credit transaction, or delivery of paregoric, U.S.P., may be completed by anonpharmacist. A pharmacist may refuse to dispense a paregoric, U.S.P.,substance until he is satisfied that the product is being obtained formedicinal purposes only.
(h) Paregoric, U.S.P., may only be sold at retail without aprescription to a person at least 18 years of age. A pharmacist must requireevery retail purchaser of a paregoric, U.S.P., substance to furnish suitableidentification, including proof of age when appropriate, in order to purchaseparegoric, U.S.P. The name and address obtained from such identification shallbe entered in the record of disposition to consumers.
(i) The Commission may by regulation except any compound,mixture, or preparation containing any stimulant or depressant substance listedin paragraphs (a)1 and (a)2 of this schedule from the application of all or anypart of this Article if the compound, mixture, or preparation contains one ormore active medicinal ingredients not having a stimulant or depressant effecton the central nervous system; and if the ingredients are included therein insuch combinations, quantity, proportion, or concentration that vitiate thepotential for abuse of the substances which have a stimulant or depressanteffect on the central nervous system.
(j) Any material, compound, mixture, or preparation whichcontains any quantity of the following substances having a stimulant effect onthe central nervous system, including its salts, isomers, and salts of saidisomers whenever the existence of such salts, isomers, and salts of isomers ispossible within the specific chemical designation, unless specifically excludedor listed in some other schedule.
1. Benzphetamine.
2. Chlorphentermine.
3. Clortermine.
4. Repealed by Session Laws 1987, c. 412, s. 10.
5. Phendimetrazine.
(k) Anabolic steroids. The term "anabolic steroid"means any drug or hormonal substance, chemically and pharmacologically relatedto testosterone (other than estrogens, progestins, and corticosteroids) thatpromotes muscle growth, including, but not limited to, the following:
1. Methandrostenolone,
2. Stanozolol,
3. Ethylestrenol,
4. Nandrolone phenpropionate,
5. Nandrolone deconoate,
6. Testosterone propionate,
7. Chorionic gonadotropin,
8. Boldenone,
9. Chlorotestosterone (4‑chlorotestosterone),
10. Clostebol,
11. Dehydrochlormethyltestosterone,
12. Dibydrostestosterone (4‑dihydrotestosterone),
13. Drostanolone,
14. Fluoxymesterone,
15. Formebulone (formebolone),
16. Mesterolene,
17. Methandienone,
18. Methandranone,
19. Methandriol,
20. Methenolene,
21. Methyltestosterone,
22. Mibolerone,
23. Nandrolene,
24. Norethandrolene,
25. Oxandrolone,
26. Oxymesterone,
27. Oxymetholone,
28. Stanolone,
29. Testolactone,
30. Testosterone,
31. Trenbolone, and
32. Any salt, ester, or isomer of a drug or substance describedor listed in this subsection, if that salt, ester, or isomer promotes musclegrowth. Except such term does not include an anabolic steroid which isexpressly intended for administration through implants to cattle or othernonhuman species and which has been approved by the Secretary of Health andHuman Services for such administration. If any person prescribes, dispenses, ordistributes such steroid for human use, such person shall be considered to haveprescribed, dispensed, or distributed an anabolic steroid within the meaning ofthis subsection.
(l) Repealed by Session Laws 2001‑233, s. 3(a).
(m) Any drug product containing gamma hydroxybutyric acid,including its salts, isomers, and salts of isomers, for which an application isapproved under section 505 of the Federal Food, Drug, and Cosmetic Act.
(n) Dronabinol (synthetic) in sesame oil and encapsulated in asoft gelatin capsule in a U.S. Food and Drug Administration approved drugproduct. [Some other names: (6aR‑trans), ‑6a,7,8,10a‑tetrahydro‑6,6,9‑trimethyl‑3‑pentyl‑6H‑dibenzo[b,d]pyran‑1‑o1 or (‑)‑delta‑9‑(trans)‑tetrahydrocannabinol].(1971, c. 919, s. 1; 1973, c. 476, s. 128; c. 540, s.5; c. 1358, ss. 7, 15; 1975, c. 442; 1977, c. 667, s. 3; 1979, c. 434, s. 3;1981, c. 51, s. 9; 1987, c. 412, ss. 8‑10; 1987 (Reg. Sess., 1988), c.1055; 1991, c. 413, s. 1; 1993, c. 319, s. 5; 1999‑370, s. 3; 2000‑140,s. 92.2(b); 2001‑233, ss. 2(b), 3(a), 3(b).)
This schedule includes the controlled substances listed or to be listedby whatever official name, common or usual name, chemical name, or trade namedesignated. In determining that a substance comes within this schedule, theCommission shall find: a potential for abuse less than the substances listed inSchedules I and II; currently accepted medical use in the United States; andabuse may lead to moderate or low physical dependence or high pyschologicaldependence. The following controlled substances are included in this schedule:
(a) Repealed by Session Laws 1973, c. 540, s. 5.
(b) Any material, compound, mixture, or preparation whichcontains any quantity of the following substances having a depressant effect onthe central nervous system unless specifically exempted or listed in anotherschedule:
1. Any substance which contains any quantity of a derivative ofbarbituric acid, or any salt of a derivative of barbituric acid.
2. Chlorhexadol.
3. Repealed by Session Laws 1993, c. 319, s. 5.
4. Lysergic acid.
5. Lysergic acid amide.
6. Methyprylon.
7. Sulfondiethylmethane.
8. Sulfonethylmethane.
9. Sulfonmethane.
9a. Tiletamine and zolazepam or any salt thereof. Some trade orother names for tiletamine‑zolazepam combination product: Telazol. Sometrade or other names for tiletamine:
2‑(ethylamino)‑2‑(2‑thienyl)‑cyclohexanone.Some trade or other names for zolazepam: 4‑(2‑fluorophenyl)‑6,8‑dihydro‑1,3,8‑trimethylpyrazolo‑[3,4‑e][1,4]‑diazepin‑7(1H)‑one. flupyrazapon.
10. Any compound, mixture or preparation containing
(i) Amobarbital.
(ii) Secobarbital.
(iii) Pentobarbital.
or any salt thereof and one or more active ingredientswhich are not included in any other schedule.
11. Any suppository dosage form containing
(i) Amobarbital.
(ii) Secobarbital.
(iii) Pentobarbital.
or any salt of any of these drugs and approved by thefederal Food and Drug Administration for marketing as a suppository.
12. Ketamine.
(c) Nalorphine.
(d) Any material, compound, mixture, or preparation containinglimited quantities of any of the following narcotic drugs, or any salts thereofunless specifically exempted or listed in another schedule:
1. Not more than 1.80 grams of codeine per 100 milliliters ornot more than 90 milligrams per dosage unit with an equal or greater quantityof an isoquinoline alkaloid of opium.
2. Not more than 1.80 grams of codeine per 100 milliliters ornot more than 90 milligrams per dosage unit, with one or more active,nonnarcotic ingredients in recognized therapeutic amounts.
3. Not more than 300 milligrams of dihydrocodeinone per 100milliliters or not more than 15 milligrams per dosage unit with a four‑foldor greater quantity of an isoquinoline alkaloid of opium.
4. Not more than 300 milligrams of dihydrocodeinone per 100milliliters or not more than 15 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
5. Not more than 1.80 grams of dihydrocodeine per 100milliliters or not more than 90 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
6. Not more than 300 milligrams of ethylmorphine per 100milliliters or not more than 15 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
7. Not more than 500 milligrams of opium per 100 milliliters orper 100 grams, or not more than 25 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts.
8. Not more than 50 milligrams of morphine per 100 millilitersor per 100 grams with one or more active, nonnarcotic ingredients in recognizedtherapeutic amounts.
(e) Any compound, mixture or preparation containing limitedquantities of the following narcotic drugs, which shall include one or moreactive, nonnarcotic, medicinal ingredients in sufficient proportion to conferupon the compound, mixture, or preparation, valuable medicinal qualities otherthan those possessed by the narcotic drug alone:
1. Paregoric, U.S.P.; provided, that no person shall purchaseor receive by any means whatsoever more than one fluid ounce of paregoricwithin a consecutive 24‑hour period, except on prescription issued by aduly licensed physician.
(f) Paregoric, U.S.P., may be dispensed at retail as permittedby federal law or administrative regulation without a prescription only by aregistered pharmacist and no other person, agency or employee may dispenseparegoric, U.S.P., even if under the direct supervision of a pharmacist.
(g) Notwithstanding the provisions of G.S. 90‑91(f), afterthe pharmacist has fulfilled his professional responsibilities and legalresponsibilities required of him in this Article, the actual cash transaction,credit transaction, or delivery of paregoric, U.S.P., may be completed by anonpharmacist. A pharmacist may refuse to dispense a paregoric, U.S.P.,substance until he is satisfied that the product is being obtained formedicinal purposes only.
(h) Paregoric, U.S.P., may only be sold at retail without aprescription to a person at least 18 years of age. A pharmacist must requireevery retail purchaser of a paregoric, U.S.P., substance to furnish suitableidentification, including proof of age when appropriate, in order to purchaseparegoric, U.S.P. The name and address obtained from such identification shallbe entered in the record of disposition to consumers.
(i) The Commission may by regulation except any compound,mixture, or preparation containing any stimulant or depressant substance listedin paragraphs (a)1 and (a)2 of this schedule from the application of all or anypart of this Article if the compound, mixture, or preparation contains one ormore active medicinal ingredients not having a stimulant or depressant effecton the central nervous system; and if the ingredients are included therein insuch combinations, quantity, proportion, or concentration that vitiate thepotential for abuse of the substances which have a stimulant or depressanteffect on the central nervous system.
(j) Any material, compound, mixture, or preparation whichcontains any quantity of the following substances having a stimulant effect onthe central nervous system, including its salts, isomers, and salts of saidisomers whenever the existence of such salts, isomers, and salts of isomers ispossible within the specific chemical designation, unless specifically excludedor listed in some other schedule.
1. Benzphetamine.
2. Chlorphentermine.
3. Clortermine.
4. Repealed by Session Laws 1987, c. 412, s. 10.
5. Phendimetrazine.
(k) Anabolic steroids. The term "anabolic steroid"means any drug or hormonal substance, chemically and pharmacologically relatedto testosterone (other than estrogens, progestins, and corticosteroids) thatpromotes muscle growth, including, but not limited to, the following:
1. Methandrostenolone,
2. Stanozolol,
3. Ethylestrenol,
4. Nandrolone phenpropionate,
5. Nandrolone deconoate,
6. Testosterone propionate,
7. Chorionic gonadotropin,
8. Boldenone,
9. Chlorotestosterone (4‑chlorotestosterone),
10. Clostebol,
11. Dehydrochlormethyltestosterone,
12. Dibydrostestosterone (4‑dihydrotestosterone),
13. Drostanolone,
14. Fluoxymesterone,
15. Formebulone (formebolone),
16. Mesterolene,
17. Methandienone,
18. Methandranone,
19. Methandriol,
20. Methenolene,
21. Methyltestosterone,
22. Mibolerone,
23. Nandrolene,
24. Norethandrolene,
25. Oxandrolone,
26. Oxymesterone,
27. Oxymetholone,
28. Stanolone,
29. Testolactone,
30. Testosterone,
31. Trenbolone, and
32. Any salt, ester, or isomer of a drug or substance describedor listed in this subsection, if that salt, ester, or isomer promotes musclegrowth. Except such term does not include an anabolic steroid which isexpressly intended for administration through implants to cattle or othernonhuman species and which has been approved by the Secretary of Health andHuman Services for such administration. If any person prescribes, dispenses, ordistributes such steroid for human use, such person shall be considered to haveprescribed, dispensed, or distributed an anabolic steroid within the meaning ofthis subsection.
(l) Repealed by Session Laws 2001‑233, s. 3(a).
(m) Any drug product containing gamma hydroxybutyric acid,including its salts, isomers, and salts of isomers, for which an application isapproved under section 505 of the Federal Food, Drug, and Cosmetic Act.
(n) Dronabinol (synthetic) in sesame oil and encapsulated in asoft gelatin capsule in a U.S. Food and Drug Administration approved drugproduct. [Some other names: (6aR‑trans), ‑6a,7,8,10a‑tetrahydro‑6,6,9‑trimethyl‑3‑pentyl‑6H‑dibenzo[b,d]pyran‑1‑o1 or (‑)‑delta‑9‑(trans)‑tetrahydrocannabinol].(1971, c. 919, s. 1; 1973, c. 476, s. 128; c. 540, s.5; c. 1358, ss. 7, 15; 1975, c. 442; 1977, c. 667, s. 3; 1979, c. 434, s. 3;1981, c. 51, s. 9; 1987, c. 412, ss. 8‑10; 1987 (Reg. Sess., 1988), c.1055; 1991, c. 413, s. 1; 1993, c. 319, s. 5; 1999‑370, s. 3; 2000‑140,s. 92.2(b); 2001‑233, ss. 2(b), 3(a), 3(b).)
